RB1 and cancer: It has been shown that ESRP1/2 activation leads to oncogenic activation of several ESRP1/2 target genes such as MAP 3 K7, mTOR, GSK3ß, RB1, CTNND1, E-Cadherin, and CD44, which drive tumor cell proliferation and EMT, key features of advanced and aggressive cancers [5, 13, 37, 38].